NuCana grabs $57 mln Series B funds

NuCana has raised $57 million in Series B funding. Sofinnova Ventures led the round with participation from Sofinnova Partners, Morningside Ventures, Alida Capital International and the Scottish Investment Bank, the investment arm of Scottish Enterprise. In addition to the funding, James Healy and Gerald Chan, co-founder and chairman of Morningside Ventures respectively, have been added to NuCana's board of directors. Based in Edinburgh, NuCana is an biopharmaceutical firm focused on anti-cancer medicines.

North AmericaUSBriefs